2023 annual financial data
Allogene Therapeutics 2023 Operating margin
Allogene Therapeutics 2023 operating margin with verified reported values.
Direct answer
Operating margin was -344,986.32%.
Operating income was -327,737,000 USD and net income was -327,265,000 USD.
Operating cash flow was -237,733,000 USD.
Get free Allogene Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 95,000 USD
- Operating income
- -327,737,000 USD
- Net income
- -327,265,000 USD
- Operating cash flow
- -237,733,000 USD